Effect of E5510 on anastomotic intimal hyperplasia and platelet aggregation in dogs

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 6, 1996, Pages 824-830

  Fujioka, K ^a,c   Esato, K ^a   Furutani, A ^a   Akiyama, N ^a   Yoshimura, K ^a   Takenaka, H ^a   Sekido, T ^b   Suganuma, A ^b   Sagami, F ^b  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b Eisai Kawashima Industrial Park ^*  (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anastomotic intimal hyperplasia; E5510; Expanded polytetrafluoroethylene graft; Platelet aggregation

Indexed keywords

ANTITHROMBOCYTIC AGENT; COLLAGEN; PLATELET DERIVED GROWTH FACTOR; SATIGREL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AORTA RECONSTRUCTION; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; GRAFT PATENCY; NONHUMAN; ORAL DRUG ADMINISTRATION; POLITEF IMPLANT; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION;

ANASTOMOSIS, SURGICAL; ANIMALS; AORTA; BLOOD PLATELETS; DOGS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HYPERPLASIA; PLATELET AGGREGATION INHIBITORS; TUNICA INTIMA;

EID: 0030023686     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199606000-00009     Document Type: Article

References (14)

1. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
2. Yasuda K, Suzuki S, Shimizu T, Sakuma M, Hashimoto M, Tanabe T. Effects of cilostazol, a platelet aggregation inhibitor, on arterial reconstructive surgery with small diameter PTFE grafts (in Japanese). J Jpn Coll Angiol 1988;28:135-9.
3. Fujimori T, Harada K, Saeki T, Kogushi M, Katayama K, Satoh M. E5510, a novel antiplatelet drug with multiple modes of action. Cardiovasc Drug Rev 1991;9:264-84.
4. Nomoto K, Saeki T, Kogushi M, Kobayashi H, Yamatsu I. Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro. Jpn J Pharmacol 1993;61:7-12.
5. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol (Lond) 1963;168:178-95.
6. Oblath RW, Buckley FO Jr, Green RM, Schwartz SI, DeWeese JA. Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole. Surgery 1978;84:37-44.
7. Hashimoto M, Tanabe T, Honma H, et al. Effects of ticlopidine, an inhibitor of platelet aggregation and aspirin in arteriole substitution (in Japanese). Blood Vessels 1980;11: 170-8.
8. Valentin LI, Sicard GA, Freeman MB, Allen BT, McGoff MA, Anderson CB. Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts. Surgery 1988;104:178-84.
9. Schmidt SP, Hunter TJ, Falkow LJ, Evancho MM, Sharp WV. Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model. J Vasc Surg 1985;2:898-906.
10. Freeman MB, Sicard GA, Valentin LI, Neuberger S, Mangino MJ, Anderson CB. The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small- diameter grafts. J Vasc Surg 1988;7:554-61.
11. 2/prostaglandin endoperoxide receptor mediated platelet activation in vitro. Eur J Pharmacol 1990;183:337-8.
12. Fujimori T, Harada K, Saeki T, et al. Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid. Arzneimittelforschung 1987;37:1143-8.
13. Fujimori T, Harada K, Yoshimura T, Yamano Y, Ogawa T, Ikeda Y. Good correlation between anti-platelet effect and intraplatelet content of E5510 in human healthy volunteers after oral administration. Thromb Haemost 1989;62:408.
14. Hasegawa M, Saito M, Furunaga Y, et al. Studies on the histochemical quantitation of cell nuclei, smooth muscle cell, various connective tissues and calcium phosphate I (in Japanese). Rinshobyori 1984;32:801-8.